Subscribe To

Price Alert Latest News Economic Calendar News

CSBR / Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. Read More

Demo Live Account See Partner Details

Content Topics

Champions

Oncology

Announce

Third

Quarter

Financial

Results

Tuesday

Stock

CSBR

Posted: Mar 11 2022, 08:30

Author Name: Accesswire

CSBR News

By Accesswire
July 20, 2023

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023

HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug d

By Zacks Investment Research
March 15, 2023

Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the

By Seeking Alpha
January 29, 2023

Champions Oncology Trades At A Sufficient Discount To R&D Capacity

CSBR runs a PDX bank. PDXs are mice models of human derived tumors. The company offers services to bio and pharma companies in pre clinical treatment

By Seeking Alpha
December 13, 2022

Champions Oncology, Inc. (CSBR) Q2 2023 Earnings Call Transcript

Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2023 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Mi

By Accesswire
December 9, 2022

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022

HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming dru

By Seeking Alpha
September 9, 2022

Champions Oncology, Inc. (CSBR) Q1 2023 Earnings Call Transcript

Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2023 Earnings Conference Call September 8, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David M

By Zacks Investment Research
September 8, 2022

Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the num

By Zacks Investment Research
March 29, 2022

Has Champions Oncology, Inc. (CSBR) Outpaced Other Medical Stocks This Year?

Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.